Poh Weijie, Ph.D., is the Global Project Manager of Healint Pte. Ltd, a migraine and headache tracking health-tech statup based in Singapore. In this role, Dr, Poh coordinates activities, ranging from real-world evidence studies, market research and marketing campaigns, with pharmaceutical, medical device and academic research institutes all over the world.
Prior to returning to Singapore, Dr. Poh co-founded and was CEO of PathoVax, a universal HPV vaccine spinoff from the Johns Hopkins University and was involved in federal and private partnerships that led to the manufacturing of clinical-grade product, GLP toxicology studies and other IND-enabling work. In 2018, Dr. Poh was appointed as Entrepreneur-in-Residence at the Duke-NUS Medical School where he was responsible for the commercialization effort of an accelerated live attenuated vaccine generation platform for emerging infectious diseases.
Dr. Poh graduated with an Ph.D. from the Johns Hopkin University School of Medicine and trained as a postdoctoral fellow at the Dana-Farber Cancer Institute in Boston.